Dr. Glimcher leads this academic medical center, a principal teaching affiliate of Harvard Medical School, with an equal commitment to patient care and cancer research. It is the only cancer center ranked in the top five nationally by U.S. News & World Report in both adult and pediatric cancer care and also ranked as New England’s top ranked cancer center for more than 20 years. Dr. Glimcher is also director of the Dana-Farber/Harvard Cancer Center and a Richard and Susan Smith Professor of Medicine at Harvard Medical School. As CEO, Dr. Glimcher has led Dana-Farber through significant growth, opening three new outpatient clinics in the last four years, and now leads an effort to build a proposed $1.7 billion adult inpatient cancer hospital. A proponent of improving access to equitable care, Dr. Glimcher has overseen establishment of community partnerships to connect patients from underserved communities to cancer prevention, education, diagnosis and care. She is committed to supporting Dana-Farber’s research, which played a substantive role in developing 51% of all FDA-approved cancer drugs between 2018 and 2023. Dr. Glimcher is a member of both National Academy of Sciences and National Academy of Medicine, a fellow of the American Academy of Arts and a former president of the American Association of Immunologists.
